AMRS Gaining Attention
Amyris Inc (NASDAQ: AMRS)
Amyris is having a strong day in the market today, and for good reason. While we haven't seen any new news today, we have seen investor excitement, as investors seem to be picking up on what the company has been putting down over the past year. Today, we'll talk about what's going on, what we're seeing in the market, and why I'm expecting to see further gains from AMRS ahead. So, let's get right to it...
AMRS Had A Fundamentally Strong Year So Far
As mentioned above, there hasn't been any new news surrounding Amyris today. However, the stock is soaring. After a bit of research, and some digging around on StockTwits, I believe that the reason for the gains is the fact that investors are finally taking note of some of the fundamental groundwork the company has laid throughout the year. While there have been several announcements throughout the year, there are 5 that I believe are the most important. Here they are:
The Illuminator – One of the big announcements made this year was the launch of the Illuminator. For some time, AMRS has worked with Biossance to come up with the product. Now, the product is on the market and will likely generate strong profits ahead.
DOE Agreement – Another big agreement announced earlier in the year was an agreement with the United States Department of Energy. According to this agreement, the company is working with the DOE to produce a key ingredient in biofuels. That ingredient is known as cellulose-derived farnesene.
Gevaudan – Another big agreement that was announced this year is an agreement between AMRS and Givaudan - a leader in flavors and fragrances around the world. According to this agreement, the two will be working together to develop proprietary fragrance ingredients.
Biogen – Another big agreement took place early on in the year. This agreement was with Biogen. Ultimately, the two companies are working to use advanced microbe engineering technology to evaluate and develop multiple host microorganisms. The ultimate goal is that Amyris and Biogen will use these microorganisms as alternatives to mammalian cell lines for the production of therapeutic recombinant proteins.
Extended Agreement – Finally, AMRS announced in late September that the company has reached an extended agreement with a global nutraceuticals leader. The extended agreement includes the addition of a new nutraceutical target, a credit line of up to $25 million with a 5-year maturity, and an option for a $5 million strategic investment.
What We're Seeing From The Stock Today
As mentioned above, Amyris is having an incredible day in the market as investors continue the chatter surrounding the foundation that has been laid this year. Currently (12:07), AMRS is trading at $0.72 per share after a gain of $0.08 per share (12.51%) thus far today
What We Can Expect To See Moving Forward As I've said in the past, my opinion with regard to Amyris is overwhelmingly bullish. At the end of the day, the company has laid a strong foundation this year that will likely send revenue and profits soaring in the years to come. All in all, I'm expecting to see gains surrounding AMRS.
Amyris Inc. (AMRS) was among the biggest gainers on the Russell 2000 for Wednesday October 12 as the stock popped 20.37% to $0.77, representing a gain of $0.1303 per share. Some 9.33 million shares traded hands on 11,138 trades, compared with an average daily volume of 2.65 million shares out of a total float of 235.02 million. The stock opened at $0.65 and traded with an intraday range of $0.78 to $0.64.
After today's gains, Amyris Inc. reached a market cap of $180.94 million. Amyris Inc. has had a trading range between $2.57 and $0.31 over the last year, and it had a 50-day SMA of $0.46 and a 200-day SMA of $0.85.
Amyris Inc is a renewable products company engaged in providing sustainable alternatives to petroleum-sourced products. It developed microbial engineering and screening technologies that modify the way microorganisms process sugars.
Amyris Inc. is based out of Emeryville, CA and has some 400 employees. Its CEO is John Melo.
